



MIGUEL ABREU

Portugal

Personal statement

I am a certified Medical Oncology Consultant by ESMO, with over 10 years of dedicated experience in the treatment of gynecologic cancer patients. I always practice at a Comprehensive Cancer Center that has treated nearly 300 new cases of gynecologic malignancies annually for more than two decades. Throughout my clinical career, I have had the opportunity to manage also rare gynecologic pathologies.

I am an active member of several prominent research groups, including the EORTC Gynecologic Cancer Group and EOTTD member (in this case also the national representative). I am also a board member of the Portuguese Research Group on Gynecologic Cancers (GPECO), an ENGOT partner.

I have participated in over 70 clinical trials, ranging from Phase I to Phase IV, acting as Principal Investigator in more than 10 studies and as national coordinator in two. I am the lead author of the two most recent ESGO-sponsored guidelines on trophoblastic disease, contributed as external revision of the pregnancy malignant guidelines of ESGO and contributed also to the last three Portuguese National Consensus statements on gynecologic cancers.

I previously led the Clinical Oncology Group at the Research Center of the Portuguese Institute of Oncology in Porto and currently serve as President of PARTNER, the Portuguese Breast Cancer Research Group.

In academia, I regularly lecture in Master's programs in Oncology and supervise PhD students in Palliative Care. I have overseen and examined numerous Master's and PhD theses. On a professional society level, I am the former President and current President of the Scientific Council of the Portuguese Society of Oncology. I founded the Portuguese Oncology Course, modeled similar to international advanced oncology courses, which has now completed over 10 successful editions.

I am also a co-organizer of the annual Advanced Portuguese Gynecologic Oncology Course. Additionally, I have organized both the EORTC Gynecologic Group Autumn Meeting and one EOTTD Meeting, and was responsible for bringing the first "Best of ASCO" event to Portugal.

Given the breadth of my professional experience, academic involvement, and leadership roles, I am confident that I possess the skills and expertise necessary to actively contribute to the continued development and success of ESGO.

CURRICULUM VITAE

Miguel Henriques Abreu(MD,PhD)

Birth: 24/8/1983

E-mail: antonio.m.abreu@ipporto.min-saude.pt

Present Titles and Affiliation

-Consultant in Medical Oncology, since 2019, dedicated to: breast, gynecological and sarcomas, Department of Medical Oncology, IPO Porto
-Competence in health services management recognized for Portuguese Medical Council, since 2025

-Member of the Direction, Portuguese study group of gynecologic cancers (GPECO), an ENGOT member, since 2022
-Medical Oncology Coordinator, Sarcoma Unit, IPO Porto, since 2023
-Emergency team leader, IPO Porto, since 2023
-Member of Policy Group, National Cancer Hub, since 2023
-Past President of the Portuguese Society of Oncology, 2022-2024
-President of the Scientific Council, Portuguese Society of Oncology, since 2024
-Member of governance committee of the RESAR (Retroperitoneal Sarcoma Registry) of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group, since 2024
-President of the Portuguese Breast Cancer Collaborative Research Group-PARTNER, since 2024

Education

- | | |
|--|------|
| • MD, ICBAS-UP, University of Porto | 2007 |
| • PhD in Medical Sciences, ICBAS-UP, University of Porto | 2016 |
| • PADIS program: AESE Business school | 2025 |

Academic Appointments

Supervision Experience

- | | |
|---|--------------|
| • PhD Thesis Supervisor in Medical Sciences, ICBAS-UP | 2019-present |
| • PhD Thesis Commission in Health Sciences, Nova Medical School, Lisbon | 2023-present |
| • Master Thesis Supervisor in Medicine, ICBAS-UP | 2016 |

Academic Juries

- | | |
|---|------|
| • Master Thesis in Medicine ICBAS-UP, Arguer | 2025 |
| • Master Thesis in Palliative Care, FM-UP, Porto, Arguer | 2021 |
| • PhD Thesis in Medicine, Nova Medical School, Lisbon, Arguer | 2020 |
| • Master Thesis in Palliative Care, FM-UP, Porto, Arguer | 2020 |

Teaching activities

- | | |
|---|---------------|
| • Master in Oncology, Clinical Oncology Module, ICBAS-UP, University of Porto | 2024- ongoing |
| • Master and PhD in Palliative Care, FM-UP, University of Porto | 2015-2021 |

Professional Certification

- European Society of Medical Oncology, ESMO (Approved) 2014
- Portuguese Board of Medical Oncology (19,7 values) 2014

Member of Collaborative Research Groups

Active member: breast: EORTC breast, SOLTI; Sarcoma: EORTC sarcoma, Euro Ewing Consortium, TARSWG; Gynecological cancers: ESGO, GPECO, EORTC Gynecological cancers.

National and International Advisory Boards

Had participated in many national and international advisory boards.

Experts Reviewer for Funding Agencies and Grants

- Science in Practice, Pharma Sponsored- MSD, Portugal, *breast and gynecological cancers* 2024
- LPCC, Portugal, *breast cancer* 2022
- Portuguese Society of Oncology, *many pathologies* 2016-2018

Editorial Boards and Peer Reviewer

The Breast, European Journal of Cancer, European Journal of Cancer Prevention, Breast Cancer: targets and therapy, Scientific reports on nature research journal, Oncotargets and therapy, BMC clinical pathology, Cancer Medicine, World Journal of Surgical Oncology.

Clinical Research as PI, Co-investigator and National Coordinator

Co-Investigator:70 clinical trials(Phase I-IV), Principal Investigator in 10, National Coordinator in 2.

Publications

Metrics:h-index=16;i10-index=21;citations: 1716

Publications list (selected)

https://scholar.google.pt/citations?user=udb_bPIAAAAJ&hl=pt-PT

Metrics: h-index=16; i10-index=21; citations: 1716

1. C. Lok, N von Trammel, El Baicru, F, Planchamp, R Bercowitz, M Seckl, **Miguel Abreu**, et al. Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD)-European Society of Gynaecologic Oncology (ESGO)-Gynecologic Cancer InterGroup (GCIg)-International Society for the Study of Trophoblastic Diseases (ISSTD, J Clin Oncol. 2025 Jun 20;43(18):2119-2128.
2. I Fernandes, D Macedo, E Gouveia, A Ferreira, J Lima, D Lopez, C Melo-Alvim, A Carvalho, P Tavares, P Rodrigues-Santos, P Cardoso, M Magalhães, P Vieira, J Brito, C Mendes, J Rodrigues, E Netto, V Oliveira, C Sousa, **M Henrique Abreu**, F Pina, H Vasques. [Practical Guidance on the Detection of NTRK Fusions in Sarcomas: Current Status and Diagnostic Challenges. Acta Med Port. 2025 Apr 1;38(4):266-275
3. E Mor, S Apte, C Mitchell, C Nessim, M Almond, B Vincenzi, JAG Lopez, L Cranmer, MJ Wagner, A Nissan, **MH Abreu**, M Albertsmeier, M Knoblauch, A Barlow, EZ Keung, G Grignani, JL Hornick, A Gronchi, DE Gyorki. Natural History of Primary Retroperitoneal Extra-Visceral Perivascular Epithelioid Cell Tumors (PEC): A Study from Transatlantic and Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). Ann Surg Oncol. 2025 Jul 14. doi: 10.1245
4. Diana Luísa Almeida-Nunes, Mariana Nunes, Hugo Osório, Verónica Ferreira, Cláudia Lobo, Paula Monteiro, **Miguel Henrique Abreu**, Carla Bartosch, Ricardo Silvestre, Ricardo Jorge Dinis-Oliveira, Sara Ricardo, Ovarian cancer ascites proteomic profile reflects metabolic changes during disease progression, Biochemistry and Biophysics Reports, 2024: 39, 101755
5. Mariana Nunes, Diana Nunes, **Miguel Abreu**, Carla Bartosch, Sara Ricardo, Que outra utilidade clínica poderão ter as ascites no carcinoma do ovário?, Revista Portuguesa de Oncologia, 2024: 7(2), 25-30
6. Mariana Nunes, Carla Bartosch, **Miguel Henrique Abreu**, Alan Richardson, Raquel Almeida, Sara Ricardo, Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options, MDPI, 2024: 13(9), 786
7. Sara M Tolaney, Valentina Guarneri, Jae Hong Seo, Josefina Cruz, **Miguel Henrique Abreu**, Masato Takahashi, Carlos Barrios, Kristi McIntyre, Ran Wei, Maria Munoz, Belen San Antonio, Astra M Liepa, Miguel Martin, Stephen RD Johnston, Pirkko-Liisa Kellokumpu-Lehtinen, Nadia Harbeck, Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer, European Journal of Cancer, 2024: 199, 113555
8. Ana R Teixeira, **Miguel H Abreu**, Metastatic Cervical Cancer: A Case That Recalls the Importance of a Multidisciplinary Approach, Cureus, 2023:15(11)

9. Carolien P Schröder, Elise van Leeuwen-Stok, Fatima Cardoso, Barbro Linderholm, Coralie Poncet, Antonio C Wolff, Vesna Bjelic-Radisic, Gustavo Werutsky, **Miguel H Abreu**, Ivana Bozovic-Spasojevic, Irma den Hoed, Aafke H Honkoop, Maartje Los, Jose P Leone, Nicola S Russell, Tineke J Smilde, Annette WG van der Velden, Catherine Van Poznak, Marije M Vleugel, Rachel L Yung, Corneel Coens, Sharon H Giordano, Kathryn J Ruddy, Quality of life in male breast cancer: prospective study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG), *The Oncologist*, 2023: 28(10), 877-883
10. Joana Cristo Santos, **Miguel Henriques Abreu**, Miriam Seoane Santos, Hugo Duarte, Tiago Alpoim, Inês Próspero, Susana Sousa, Pedro Henriques Abreu, Bone Metastases Detection in Patients with Breast Cancer: Does Bone Scintigraphy Add Information to PET/CT?, *The Oncologist*, 2023: 28(8), 600-605
11. **Miguel Henriques Abreu**, Gabriella Lillsunde-Larsson, Carla Bartosch, Sara Ricardo, New molecular approaches to improve gynecological cancer management, *Frontiers in Oncology*, 2023: 13, 1235035
12. Kristina Lindemann, **Miguel Abreu**, Maria de Lurdes Batarda, Dorry Boll, Anne Weng Ekmann-Gade, Jesper Hansen, Ala Jabri Haug, Claus HÃ, gdall, Jacob Korach, Els Van Nieuwenhuysen, PB Ottevanger, Stephan Polterauer, Tine Henrichsen Schnack, Trude Agesen, Sofia Waldemarson, Klaus Kaae Andersen, Christian Marth, Ovarian cancer and bevacizumab: Real-world use across western countries and effect on survival in high-risk subgroups, *Journal of Clinical Oncology*, 2023: 41, 5587-5587
13. N Harbeck, V Guarneri, JH Seo, J Cruz Jurado, **MH Abreu**, M Takahashi, CH Barrios, K McIntyre, RJ Wei, B San Antonio, AM Liepa, M Martin Jimenez, SRD Johnston, SM Tolaney, 93MO Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy for adjuvant HR+, HER2-, node-positive, high-risk, early breast cancer (EBC), *ESMO Open*, 8(1), 2023
14. LÍgia Pires-Gonçalves, **Miguel Henriques Abreu**, Anabela Ferrão, António Guimarães dos Santos, Ana Teresa Aguiar, Margarida Gouvêa, Rui Henrique, Patient perspectives on repeated contrast-enhanced mammography and magnetic resonance during neoadjuvant chemotherapy of breast cancer, *Acta Radiologica*, 2023: 64(5), 1816-1822.
15. Susana Silva, Regina A Silva, Verónica Ferreira, Cláudia Lobo, Paula Monteiro, **Miguel Henriques Abreu**, Carla Bartosch, Sara Ricardo, Cytochemical characterization of ascitic fluid from a patient with ovarian cancer-a case report, 2023: 1, 27
16. Carolien P Schröder, Elise van Leeuwen-Stok, Fatima Cardoso, Barbro Linderholm, Coralie Poncet, Antonio C Wolff, Vesna Bjelic-Radisic, Gustavo Werutsky, **Miguel H Abreu**, Ivana Bozovic-Spasojevic, Irma den Hoed, Aafke H Honkoop, Maartje Los, Jose P Leone, Nicola S Russell, Tineke J Smilde, Annette WG van der Velden, Catherine Van Poznak, Marije M Vleugel, Rachel L Yung, Corneel Coens, Sharon H Giordano, Kathryn J Ruddy, Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program, 2023: 20, 1-7

17. CE Geyer Jr, JE Garber, RD Gelber, Greg Yothers, M Taboada, L Ross, P Rastogi, K Cui, A Arahmani, G Aktan, Anne C Armstrong, M Arnedos, J Balmaña, J Bergh, J Bliss, S Delaloge, SM Domchek, A Eisen, F Elsayf, LE Fein, A Fielding, JM Ford, S Friedman, KA Gelmon, L Gianni, M Gnant, SJ Hollingsworth, S-A Im, A Jager, Ó Þ Jóhannsson, SR Lakhani, W Janni, B Linderholm, T-W Liu, N Loman, L Korde, S Loibl, PC Lucas, F Marmé, E Martinez de Dueñas, R McConnell, K-A Phillips, M Piccart, G Rossi, R Schmutzler, Elżbieta Senkus, Z Shao, P Sharma, CF Singer, T Španić, E Stickeler, M Toi, TA Traina, G Viale, G Zoppoli, YH Park, R Yerushalmi, H Yang, D Pang, KH Jung, A Mailliez, Z Fan, Isabelle Tennevet, J Zhang, T Nagy, GS Sonke, Q Sun, M Parton, MA Colleoni, M Schmidt, AM Brufsky, Wajeeha Razaq, B Kaufman, D Cameron, C Campbell, ANJ Tutt, Paul Sevela, Ferdinand Haslbauer, Monika Penzinger, Leopold Öhler, Christoph Tinchon, Richard Greil, Sonja Heibl, Rupert Bartsch, Viktor Wette, Christian F Singer, Claudia Pasterk, Ruth Helfgott, Gunda Pristauz-Telsnigg, Herbert Stöger, Angsar Weltermann, Daniel Egle, Irene Thiel, David Fuchs, Holger Rumpold, Kathrin Strasser-Weippl, Beate Rautenberg, Volkmar Müller, Marcus Schmidt, Stefan Paepke, Mustafa Aydogdu, Christoph Thomssen, Joachim Rom, Christine Mau, Peter Fasching, Uwe-Jochen Göhring, Thorsten Kühn, Stefanie Noeding, Sherko Kümmel, John Hackmann, Elmar Stickeler, Abhishek Joshi, Joanna Dewar, Michael Friedlander, Kelly-Anne Phillips, Yolanda Antill, Natasha Woodward, Ehtesham Abdi, Susan Tiley, Mathew George, David Boodle, Annabel Goodwin, Andre van der Westhuizen, George Kannourakis, Nicholas Murray, Nicole McCarthy, Judith Kroep, Maaïke de Boer, Joan Heijns, Agnes Jager, Franciscus Erdkamp, Sandra Bakker, Gabe S Sonke, Amer Sami, John Mackey, Catherine Prady, Andrea Eisen, Christine Desbiens, Erica Patocskai, Cristiano Ferrario, Karen Gelmon, Louise Bordeleau, Haji Chalchal, Saroj Niraula, Elżbieta Senkus, François Duhoux, Randal d'Hondt, Sylvie Luce, Daphné t'Kint de Roodenbeke, Konstantinos Papadimitriou, Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer, *Annals of oncology*, 2022: 33(12), 1250-1268.

18. Sarah Lopes, Iolanda Vieira, **Miguel Abreu**, Inês Pousa, Ana Ferreira, Susana Sousa, Deolinda Pereira, Prognostic factors and survival according to tumor subtype in women with breast cancer brain metastases, *Current Problems in Cancer*, 2022: 46(6), 100866.

19. Christian Marth, **Miguel Henriques Abreu**, Klaus Kaae Andersen, Karoliina M Aro, Maria de Lurdes Batarda, Dorry Boll, Anne Weng Ekmann-Gade, Ulla-Maija Haltia, Jesper Hansen, Ala Jabri Haug, Claus Høgdall, Jacob Korach, Heini Lassus, Kristina Lindemann, Els Van Nieuwenhuysen, Petronella B Ottevanger, Stephan Polterauer, Tine Henrichsen Schnack, Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial), 2022: 128(16), 3080-3089.

20. Denise Magalhães, Carla Bartosch, **Miguel H Abreu**, Do not forget poly (adenosine diphosphate-ribose) polymerase inhibitors in ovarian carcinosarcoma, *Cureus*, 2022: 14(7)

21. Inês Moreira, Ana Afonso, **Miguel Abreu**, Susana Sousa, Marta Ferreira, Everolimus and exemestane in hormone receptor positive advanced breast cancer: A comprehensive cancer center's experience, *Bulletin du Cancer*, 2022: 109(6), 723-725.

22. Ana Torres Rebelo, Joana Monteiro, **Miguel Henriques Abreu**, Desmoid-Type Fibromatosis in a Young Male, Acta Médica Portuguesa, 2022: 35(5), 392-393.

23. Bárbara Lima, **Miguel Henriques Abreu**, Susana Sousa, Carla Bartosch, Deolinda Pereira, Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation, Gynecologic Oncology Reports, 2022: 40, 100942.

24. I Vergote, A González-Martín, I Ray-Coquard, P Harter, N Colombo, P Pujol, D Lorusso, MR Mirza, B Brasiuniene, R Madry, JD Brenton, MGEM Ausems, R Büttner, D Lambrechts, M Ausems, J Brenton, **M Abreu**, S Balboni, S Banerjee, M Barberis, MP Barretina Ginesta, J-F Baurain, M Bignami, L Bjorge, P Blecharz, I Bruchim, M Capilna, N Cerana, A Cicchetti, D Collins, N Concin, M D'Incalci, B Davidson, T de la Motte Rouge, P De Iaco, F Demirkiran, H Denys, T Doerk, A Dorum, A Ferrero, AP Fidalgo, M Genuardi, L Gladieff, R Glasspool, C Grimm, M Gultekin, E Hahnen, A Hasenburg, A Hegmane, V Heinzelmann, E Hogdall, R Janavicius, S Jarmalaite, R Kalachand, R Kaneva, S Kilickap, R Kocian, D Kolencik, R Kristeleit, A Kryzhanivska, A Leary, B Lemley, M Ligtenberg, JA López-Guerrero, CJ Lord, E Avall-Lundqvist, J Maenpaa, S Mahner, F Marmé, C Marth, I McNeish, S Merkelbach-Bruse, M Mourits, N Normanno, A Oaknin, K Ojamaa, C Papdimitriou, F Penault-Llorca, AM Perrone, S Pignata, E Pikarsky, E Rouleau, M Rubio, A Sapino, B Schmalfeldt, J Sehouli, R Shapira, KD Steffensen, V Sukhin, J Syrjos, Z Szallasi, C Taskiran, M Terzic, M Tischkowitz, I Toth, K Van de Vijver, MA Vardar, B Wasag, P Wimberger, E Witteveen, European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer, Annals of Oncology, 2022: 33(3), 276-287.

25. Lígia Pires-Gonçalves, **Miguel Henriques Abreu**, Ana Teresa Aguiar, António Guimarães Dos Santos, Anabela Ferrão, Rui Henrique, Size reduction and decreased enhancement of benign breast fibroadenoma on contrast-enhanced mammography during neoadjuvant chemotherapy, Diagnostic and interventional imaging, 2022: 103(2), 121-122.

26. Ana Paula Vasconcelos,(...) **Miguel Henriques Abreu**, Joana S. Monteiro. X Consenso Nacional de Cancro da Mama- Sociedade Portuguesa de Senologia 2022.

27. **Miguel Henriques Abreu**, Marta Ferreira. Immonotherapy for Gynaecological Cancers. In book: The EBCOCG Postgraduate Textbook of Obstetrics & Gynaecology. 202, DOI: 10.1017/9781108582322.061

28. JP Amorim, PH Abreu, A Fernández, M Reyes, J Santos, **MH Abreu**. Interpreting deep machine learning models: an easy guide for oncologists. IEEE Reviews in Biomedical Engineering 2021: 16, 192-207

29. MS Moura, E Cipriano, P Lopes, M Afonso, **MH Abreu**, C Bartosch. Primary versus metastatic uterine leiomyosarcoma: differences in hormonal receptors' expression. VIRCHOWS ARCHIV 2021: 479 (SUPPL 1), S26-S27

30. Javier Cortes, Fatima Cardoso, Giuseppe Curigliano, William J Gradishar, Seock-Ah Im, Hope S Rugo, Shakeela W Bahadur, Alfredo Falcone, Serafin Morales Murillo, David A

Riseberg, Antonino Musolino, Trevor M Feinstein, **Miguel H Abreu**, Young-Hyuck Im, Yelena Novik, Timothy Pluard, Lupe G Salazar, Rossana Berardi, Viorela Pop, SY Hong, Kenneth Jacobs, Edwin Rock, Mark D Pegram. Infusion related reactions in the phase 3 SOPHIA trial of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in patients with pretreated HER2+ metastatic breast cancer. *CANCER RESEARCH* 2021: 81 (4)

31. M Nunes, **M Henriques Abreu**, C Bartosch, S Ricardo. Recycling the purpose of old drugs to treat ovarian cancer. *International Journal of Molecular Sciences* 2021: 21 (20), 7768

32. Alexandra Pregal, et al. Consensos Nacionais de Ginecologia Oncológica 2020.

33. Ana Peixoto, Pedro Pinto, Joana Guerra, Manuela Pinheiro, Catarina Santos, Carla Pinto, Rui Santos, Carla Escudeiro, Carla Bartosch, Rita Canário, Ana Barbosa, Alfredo Gouveia, Almerinda Petiz, **Miguel Henriques Abreu**, Susana Sousa, Deolinda Pereira, João Silva, Manuel R Teixeira. Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects. *Frontiers in Oncology* 2020: 10, 1318

34. C Lok, N van Trommel, L Massuger, F Golfier, M Seckl, **MH Abreu**, J Attia, et al. Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease. *European Journal of Cancer* 2020: 130, 228-240

35. Iolanda Vieira, **Miguel Abreu**, Tiago Alpoim, Isabel Pereira, Susana Sousa, Isabel Azevedo, Machado Carvalho, Deolinda Pereira. Patterns of development and prognostic factors in central nervous system metastasis according to breast cancer subtypes. *CANCER RESEARCH* 2020: 80 (4)

36. S Coelho, **MH Abreu**, C Sales, AR Lopes, MF Sousa, R Couto, I Pousa, A Ferreira, M Ferreira, C Vieira, C Leal, F Castro, S Sousa, D Pereira. Carboplatin-addition in neoadjuvant treatment of women with triple negative breast cancer (TNBC): Prognostic value in real-world patients. *CANCER RESEARCH* 2019: 79 (4)

37. A Tomé, I Leal, C Palmeiras, E Matos, J Amado, **M Abreu**, C Lopes. C-ERB-2, P53, Ki67 proteins and receptors of estrogen and progesterone on the prognosis of epithelial ovarian cancer. *Current Opinion in Gynecology and Obstetrics*. *Current Opinion in Gynecology and Obstetrics* 2019: 2 (1), 169-179

38. António Tomé, Irene Leal, Carlos Palmeiras, Eduarda Matos, João Amado, **Miguel Abreu**, Carlos Lopes. DNA content evaluation for epithelial ovarian cancer identification. *Current Gynecologic Oncology* 2018: 1 (16), 3-10

39. **Miguel Henriques Abreu**, Pedro Henriques Abreu, Noémia Afonso, Deolinda Pereira, Rui Henrique, Carlos Lopes. Patterns of recurrence and treatment in male breast cancer: A clue to prognosis? *International Journal of Cancer* 2016: 139 (8), 1715-1720

40. PH Abreu, MS Santos, **MH Abreu**, B Andrade, DC Silva. Predicting breast cancer recurrence using machine learning techniques: a systematic review. *ACM Computing Surveys (CSUR)* 2016: 49 (3), 1-40

41. **MH Abreu**, N Afonso, PH Abreu, F Menezes, P Lopes, R Henrique, Deolinda Pereira, Carlos Lopes. Male breast cancer: Looking for better prognostic subgroups. *The Breast* 2016: 26, 18-24

42. **MH Abreu**, M Gomes, F Menezes, N Afonso, PH Abreu, R Medeiros, D Pereira, C Lopes. CYP2D6* 4 polymorphism: A new marker of response to hormonotherapy in male breast cancer? *The Breast* 2015: 24 (4), 481-486

43. PJ García-Laencina, PH Abreu, **MH Abreu**, N Afonso. Missing data imputation on the 5-year survival prediction of breast cancer patients with unknown discrete values. *Computers in biology and medicine* 2015: 59, 125-133